Cargando…

Corrigendum: Ligand-based CAR T-cell: Different strategies to drive T-cells in future new treatments

Detalles Bibliográficos
Autores principales:	Ramírez-Chacón, Alejandro, Betriu-Méndez, Sergi, Bartoló-Ibars, Ariadna, González, Azucena, Martí, Mercè, Juan, Manel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9721137/ https://www.ncbi.nlm.nih.gov/pubmed/36479103 http://dx.doi.org/10.3389/fimmu.2022.1078003

Ejemplares similares

Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments
por: Ramírez-Chacón, Alejandro, et al.
Publicado: (2022)

CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?
por: Bartoló-Ibars, Ariadna, et al.
Publicado: (2021)

CAR T-cells: Driving in the Fast Lane
por: Ansell, Stephen M., et al.
Publicado: (2019)

CAR-T Cells: Future Perspectives
por: Charrot, Sarah, et al.
Publicado: (2019)

Redox driven B(12)-ligand switch drives CarH photoresponse
por: Poddar, Harshwardhan, et al.
Publicado: (2023)

Promoter choice: Who should drive the CAR in T cells?
por: Rad S. M., Ali Hosseini, et al.
Publicado: (2020)

CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
por: Karschnia, Philipp, et al.
Publicado: (2021)

Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR
por: Zhang, Angela Q., et al.
Publicado: (2023)

Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma
por: Sjöstrand, Maria, et al.
Publicado: (2023)

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
por: Herrera, Lara, et al.
Publicado: (2021)

Corrigendum: Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells
por: Dwivedi, Alka, et al.
Publicado: (2019)

Drive your car into the ground.
por: Schmidt, C W
Publicado: (2001)

Challenges of driving CD30-directed CAR-T cells to the clinic
por: Grover, Natalie S., et al.
Publicado: (2019)

Erlotinib Promotes Ligand-Induced EGFR Degradation in 3D but Not 2D Cultures of Pancreatic Ductal Adenocarcinoma Cells
por: Betriu, Nausika, et al.
Publicado: (2021)

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers
por: Blanco, Belén, et al.
Publicado: (2022)

CAR T Cell Toxicity: Current Management and Future Directions
por: Yáñez, Lucrecia, et al.
Publicado: (2019)

The Past, Present, and Future of Non-Viral CAR T Cells
por: Moretti, Alex, et al.
Publicado: (2022)

CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future
por: Zhang, Zhengchao, et al.
Publicado: (2022)

Rejuvenating Effector/Exhausted CAR T Cells to Stem Cell Memory–Like CAR T Cells By Resting Them in the Presence of CXCL12 and the NOTCH Ligand
por: Ando, Makoto, et al.
Publicado: (2021)

Driving CARs to BARs: The Winding Road to Specific Regulatory T Cells for Tolerance
por: Scott, David W.
Publicado: (2021)

NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness
por: Bachiller, Mireia, et al.
Publicado: (2021)

Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy
por: Lee, Lydia, et al.
Publicado: (2023)

CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation
por: Bajgain, Pradip, et al.
Publicado: (2018)

Corrigendum: Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers
por: Feng, Qiang, et al.
Publicado: (2022)

CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
por: Rodríguez-Lobato, Luis Gerardo, et al.
Publicado: (2020)

Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
por: Hosseinkhani, Negar, et al.
Publicado: (2020)

Production and Application of CAR T Cells: Current and Future Role of Europe
por: Vucinic, Vladan, et al.
Publicado: (2021)

Correction: Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy
Publicado: (2023)

Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and tumor microenvironment, overcoming multiple obstacles of CAR T therapy for solid tumors
por: Wang, Yufeng, et al.
Publicado: (2023)

Drive the Car(go)s—New Modalities to Control Cargo Trafficking in Live Cells
por: Mondal, Payel, et al.
Publicado: (2017)

Driving CAR T Stem Cell Targeting in Acute Myeloid Leukemia: The Roads to Success
por: Michelozzi, Ilaria M., et al.
Publicado: (2021)

Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
por: Meng, Yuan, et al.
Publicado: (2021)

Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment
por: Wang, Yufeng, et al.
Publicado: (2023)

CERN cars drive by the Geneva Motor Show
por: CERN Bulletin
Publicado: (2011)

Hands-On Vision and Behavior for Self-Driving Cars
por: Venturi, Luca, et al.
Publicado: (2020)

Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity
por: Zanetti, Samanta Romina, et al.
Publicado: (2020)

A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers
por: Wong, Derek P., et al.
Publicado: (2022)

The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology
por: Mohseni, Yasmin R., et al.
Publicado: (2020)

CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions
por: Mardiana, Sherly, et al.
Publicado: (2020)

CAR-T cell therapy for lung cancer: a promising but challenging future
por: Zhong, Shupeng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1pa4e3i7g8mp0afe558hvg6dmd